Ventrus Biosciences, Inc. — 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. This is an annual report, not a quarterly filing. Registrant identity: The filing names Ventrus Biosciences, Inc.; the request metadata names Assembly Biosciences, Inc. Verify that this filing is for the intended company.
Business context
Ventrus was a development-stage specialty pharmaceutical company with no approved products or product revenue. Its pipeline targeted lower gastrointestinal disorders: VEN 309 (iferanserin) for hemorrhoids, VEN 307 (diltiazem) for anal fissure pain, and VEN 308 (phenylephrine) for fecal incontinence associated with IPAA. The company owned VEN 309 following its November 2011 acquisition from Amer and licensed VEN 307 and VEN 308 from S.L.A. Pharma.
Financial performance and liquidity
| Metric | FY 2011 / December 31, 2011 | Prior comparable period |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $25.28 million | $1.85 million in 2010 |
| General and administrative expense | $8.72 million | $2.92 million in 2010 |
| Operating loss | $34.00 million | $4.77 million in 2010 |
| Net loss | $34.34 million; $3.57 per share | $15.29 million; $24.67 per share in 2010 |
| Operating cash flow | $(25.07) million | $(5.21) million in 2010 |
| Cash and cash equivalents | $36.98 million | $14.57 million at year-end 2010 |
| Total current assets / current liabilities | $37.04 million / $2.51 million | $14.59 million / $1.72 million at year-end 2010 |
| Total liabilities | $2.51 million; no borrowings reported at year-end | $2.99 million at year-end 2010 |
| Stockholders’ equity | $34.53 million | $11.63 million at year-end 2010 |
Margins are not meaningful because the company had no revenue. The 2011 R&D expense includes a $12.5 million charge for acquiring VEN 309, treated as in-process R&D with no alternative future use. The July 2011 equity offering generated approximately $47.57 million net proceeds; 2011 financing cash flow was $47.49 million after repayments and other financing activity. Management expected available cash to fund operations into the third quarter of 2013. It also stated that additional financing would be needed to complete development programs.
Material changes, outlook, and risks
- Operating expenses rose substantially as the company resumed development activity and began a U.S. Phase III trial for VEN 309. Net loss increased versus 2010, while cash increased following the public offering. Interest expense fell sharply from 2010, which included significant noncash convertible-debt charges.
- VEN 309’s first U.S. Phase III trial began enrolling in August 2011. Management expected enrollment completion around April 2012 and top-line results around June 2012. The FDA had not issued an SPA agreement letter; its protocol recommendations were not binding. Further Phase III, recurrence, pharmacology, toxicology, and carcinogenicity work remained necessary, and an NDA filing was projected no earlier than 2014.
- S.L.A. Pharma completed enrollment of 465 patients in the European VEN 307 Phase III trial in December 2011; results were expected in May 2012. U.S. development plans depended on trial results, the assessment of a possible extended-release formulation, regulatory considerations, intellectual property, and available capital.
- VEN 308 was not an active near-term development priority. A Phase IIb program and potential orphan NDA were contingent on positive results for other candidates and sufficient funding.
- Principal risks include clinical failure or safety findings, regulatory delay or rejection, lack of additional capital, reliance on licensors, CROs and contract manufacturers, uncertain reimbursement and market adoption, and patent challenges. VEN 309 also has potential CYP2D6 drug-interaction concerns and requires further cardiac and long-term safety studies.
- The filing reports effective disclosure controls and internal control over financial reporting at year-end; the auditor issued unqualified opinions on the financial statements and internal controls. Management said previously identified control weaknesses had been remediated.
Important facts to verify
- Confirm the intended registrant: the supplied filing is for Ventrus Biosciences, not Assembly Biosciences.
- Reconcile conflicting figures within the filing text: audited statements report 2011 net loss of $34.34 million and total assets of $37.05 million, while the selected-data section shows different amounts; the risk-factor discussion also gives a different accumulated-deficit figure from the audited statements.
- Check the audited statements and notes for the VEN 309 acquisition accounting, cash runway assumptions, and remaining S.L.A. Pharma payment obligations.
- Track VEN 309 and VEN 307 trial readouts, protocol/regulatory feedback, required follow-on studies, and the funding needed to advance each program.